Acceleron Pharma, Inc. today announced the pricing of its initial public
offering of 5,580,000 shares of common stock at a public offering price
of $15.00 per share, before underwriting discounts. In addition,
Acceleron has granted the underwriters a 30-day option to purchase up to
an additional 837,000 shares of common stock at the public offering
price, less underwriting discounts. Separately, in a concurrent,
side-by-side private placement, Acceleron's collaboration partner,
Celgene Corporation CELG, has agreed to purchase 666,667 shares
of common stock from Acceleron at the public offering price. Acceleron's
common stock has been approved for listing on the NASDAQ Global Market
and is expected to begin trading under the ticker symbol “XLRN” on
September 19, 2013.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in